Organon & Company Aktie 111523364 / US68622V1061
14.57
USD
0.14
USD
0.97%
20.12.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Organon Company Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Organon & Company | 7.77 | 1.12 | USD |
| 2022 | Organon & Company | 4.01 | 1.12 | USD |
| 2021 | Organon & Company | 1.84 | 0.56 | USD |
| 2020 | Organon & Company | - | - | USD |
| 2019 | Organon & Company | - | - | USD |
| 2018 | Organon & Company | - | - | USD |
| 2017 | Organon & Company | - | - | USD |
Gewinn je Aktie- Organon & Company
| 4.0 23 | 3.6 22 | 5.3 21 | 8.5 20 | 12.7 19 | 8.5 18 | 7.1 17 |
Umsatz je Aktie- Organon & Company
| 24.4 23 | 24.2 22 | 25.1 21 | 32.0 20 | 37.6 19 | 38.6 18 | 41.5 17 |
KGV- Organon & Company
| 3.6 23 | 7.8 22 | 5.7 21 |
Organon & Company: Die Aktie (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 3.99 | 3.59 | 5.31 | 8.53 | 12.71 | 8.51 | 7.11 |
| Gewinn je Aktie unverwässert | 4.01 | 3.61 | 5.33 | 8.53 | 12.71 | 8.51 | 7.11 |
| Gewinn je Aktie verwässert | 3.99 | 3.59 | 5.33 | 8.53 | 12.71 | 8.51 | 7.11 |
| Dividende pro Aktie | 1.12 | 1.12 | 0.56 | - | - | - | - |
| Gesamtdividendenausschüttung in Mio. | 294.00 | 290.00 | 145.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Organon & Company: Unternehmenskennzahlen (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 24.44 | 24.20 | 25.08 | 31.98 | 37.65 | 38.62 | 41.48 |
| KGV (Jahresendkurs, EPS unverwässert) | 3.61 | 7.77 | 5.71 | - | - | - | - |
| KGV (Jahresendkurs, EPS verwässert) | 3.61 | 7.77 | 5.71 | - | - | - | - |
| KGV (Jahresendkurs) | 3.61 | 7.77 | 5.71 | - | - | - | - |
| Dividendenrendite Jahresende in % | 7.77 | 4.01 | 1.84 | - | - | - | - |
| Eigenkapitalquote in % | -0.58 | -8.14 | -14.12 | 55.30 | 66.70 | 60.49 | - |
| Fremdkapitalquote in % | 100.58 | 108.14 | 114.12 | 44.70 | 33.30 | 39.51 | - |
Organon & Company: GuV (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 6’263.00 | 6’174.00 | 6’360.00 | 8’096.00 | 9’530.00 | 9’777.00 | 10’500.00 |
| Umsatzveränderung in % | 1.44 | -2.92 | -21.44 | -15.05 | -2.53 | -6.89 | - |
| Bruttoergebnis vom Umsatz | 3’748.00 | 3’894.00 | 3’978.00 | 4’752.00 | 5’916.00 | 5’091.00 | 5’912.00 |
| Bruttoergebnisveränderung in % | -3.75 | -2.11 | -16.29 | -19.68 | 16.21 | -13.89 | - |
| Operatives Ergebnis | 1’327.00 | 1’719.00 | 1’872.00 | 2’782.00 | 3’662.00 | 2’713.00 | 3’272.00 |
| Veränderung Operatives Ergebnis in % | -22.80 | -8.17 | -32.71 | -24.03 | 34.98 | -17.08 | - |
| Ergebnis vor Steuern | 673.00 | 1’122.00 | 1’529.00 | 2’680.00 | 3’555.00 | 2’729.00 | 3’099.00 |
| Veränderung Ergebnis vor Steuern in % | -40.02 | -26.62 | -42.95 | -24.61 | 30.27 | -11.94 | - |
| Ergebnis nach Steuer | 1’023.00 | 917.00 | 1’351.00 | 2’160.00 | 3’218.00 | 2’153.00 | 1’801.00 |
| Veränderung Ergebnis nach Steuer in % | 11.56 | -32.12 | -37.45 | -32.88 | 49.47 | 19.54 | - |
Organon & Company: Bilanz (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 12’128 | 11’847 | 12’189 | 4’434 | 3’513 | 4’146 | - |
| Langzeit Gesamtverbindlichk. pro Aktie | 36.03 | 36.70 | 37.83 | 7.70 | 8.58 | 10.28 | - |
| Eigenkapital | -70 | -892 | -1’508 | 5’486 | 7’035 | 6’348 | - |
| Veränderung Eigenkapital in % | 92.15 | 40.85 | -127.49 | -22.02 | 10.82 | - | - |
| Bilanzsumme | 12’058 | 10’955 | 10’681 | 9’920 | 10’548 | 10’494 | - |
| Veränderung Bilanzsumme in % | 10.07 | 2.57 | 7.67 | -5.95 | 0.51 | - | - |
Organon & Company: Sonstige Angaben (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 4.01 | 3.61 | 5.33 | 8.53 | 12.71 | 8.51 | 7.11 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 11.05 | -32.27 | -37.56 | -32.88 | 49.47 | 19.54 | - |
| Gewinn je Aktie (verwässert) | 3.99 | 3.59 | 5.33 | 8.53 | 12.71 | 8.51 | 7.11 |
| Veränderung Gewinn je Aktie (verwässert) in % | 11.08 | -32.55 | -37.56 | -32.88 | 49.47 | 19.54 | - |
| Anzahl Mitarbeiter | 10’000 | 10’000 | 9’300 | 9’950 | 10’445 | - | - |
| Veränderung Anzahl Mitarbeiter in % | 0.00 | 7.53 | -6.53 | -4.74 | - | - | - |
Organon & Company Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Organon & Company | Quartalszahlen | 13.02.2025 |
| Organon & Company | Quartalszahlen | 01.05.2025 |
| Organon & Company | Quartalszahlen | 12.08.2025 |
| Organon & Company | Quartalszahlen | 30.10.2025 |
Organon & Company vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 31.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 06.08.2024 |
| Hauptversammlung | Annual General Meeting | 04.06.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 02.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 15.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 02.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 08.08.2023 |
| Hauptversammlung | Annual General Meeting | 06.06.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 04.05.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 16.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 03.11.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 04.08.2022 |
| Hauptversammlung | Annual General Meeting | 07.06.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 05.05.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 17.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.78 |
| The Vanguard Group, Inc. | 11.88 |
| Vanguard Group, Inc. (Subfiler) | 11.55 |
| BlackRock Fund Advisors | 8.84 |
| iShares Core S&P Small Cap ETF | 6.47 |
| Mawer Investment Management Ltd. | 4.99 |
| Massachusetts Financial Services Co. | 3.79 |
| SSgA Funds Management, Inc. | 3.69 |
| State Street Corp. | 3.49 |
| Vanguard Total Stock Market ETF | 3.14 |
| LSV Asset Management | 2.91 |
| Nordea Investment Management AB (Denmark) | 2.62 |
| BlackRock Institutional Trust Co. NA | 2.55 |
| Vanguard Small Cap Index Fund | 2.51 |
| Janus Henderson Contrarian Fund | 2.16 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 10’445 | 9’950 | 9’300 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.00 | 0.00 | 0.91 | 0.81 | 0.68 |
Bilanz (in Mio. USD) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 0 | 3’714 | 3’955 | 3’378 | 3’760 |
| Summe Anlagevermögen | 0 | 6’780 | 6’593 | 6’542 | 6’921 |
| Summe Aktiva | 0 | 10’494 | 10’548 | 9’920 | 10’681 |
Bilanz (in Mio. USD) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 0 | 4’146 | 3’513 | 4’434 | 12’189 |
| Summe Eigenkapital | 0 | 6’348 | 7’035 | 5’486 | -1’508 |
| Summe Passiva | 0 | 10’494 | 10’548 | 9’920 | 10’681 |
Adresse
| 30 Hudson Street, 07302 Jersey City | |
| Telefon | +1 (551) 430-6900 |
| URL | http://www.organon.com |
Management
|
Aaron Falcione
Chief Human Resources Officer |
|
Carrie Smith Cox
Chairman |
|
Charlotte Owens
Head-Medical Affairs & Outcomes Research |
|
Cynthia M. Patton
Independent Director |
|
Daniel Karp
Chief Business Development Officer |
|
Deborah R. Leone
Independent Director |
|
Grace Puma Whiteford
Independent Director |
|
Helene D. Gayle
Independent Director |
|
Jennifer Halchak
Head-Investor Relations |
|
Joseph T. Morrissey
Executive VP, Head-Manufacturing & Supply |
|
Juan Camilo Arjona Ferreira
Chief Medical Officer & Head- R&D |
|
Kate C. Liebelt
Chief of Staff & Executive Director |
|
Kathryn DiMarco
Senior Vice President-Finance & Controller |
|
Kevin Ali
Chief Executive Officer & Director |
|
Kirke Weaver
Secretary, Executive VP & General Counsel |
|
Ma. Fatima D. de Vera Francisco
Independent Director |
|
Marcel van Duin
Chief Scientific Officer |
|
Matthew M. Walsh
Chief Financial Officer & Executive Vice President |
|
Michael Pergine
Chief Government Affairs & Policy Officer |
|
Philip O. Ozuah
Independent Director |
|
R. Alan B. Ezekowitz
Independent Director |
|
Rachel A. Stahler
Chief Information Officer & Executive VP |
|
Rebecca Lowell Edwards
Chief Communications Officer |
|
Robert A. Essner
Independent Director |
|
Rochelle B. Lazarus
Independent Director |
|
Shalini Sharp
Independent Director |
|
Susan O'Neal
Chief Ethics & Compliance Officer |
|
Susanne Gabriele Fiedler
Chief Commercial Officer & Executive VP |
|
Vittorio Nisita
Executive VP & Head-Global Business Services |